Nature Search

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

SARS-CoV-2 is causing a global pandemic in which the implementation of serology can support decision making in different scenarios. Here, the authors compare the outcome of eight commercially available assays to virus neutralization and discuss their use in diagnostics and exposure assessment of SARS-CoV-2.

Corine H. GeurtsvanKessel
Nisreen M. A. Okba
Marion Koopmans
ResearchOpen Access06 Jul 2020
Nature Communications

Volume: 11, P: 1-5
A human monoclonal antibody blocking SARS-CoV-2 infection

Vaccines and targeted therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are currently lacking. Here, the authors report a human monoclonal antibody capable of neutralizing both authentic SARS-CoV and SARS-CoV-2 by targeting a common epitope.

Chunyan Wang
Wentao Li
Berend-Jan Bosch
ResearchOpen Access04 May 2020
Nature Communications

Volume: 11, P: 1-6
SARS-CoV-2 is transmitted via contact and via the air between ferrets

SARS-CoV-2 has rapidly spread globally and animal models to study transmission are needed. Here, Richard et al. show efficient transmission of SARS-CoV-2 between ferrets via direct contact and via the air, through respiratory droplets and/or aerosols.

Mathilde Richard
Adinda Kok
Sander Herfst
ResearchOpen Access08 Jul 2020
Nature Communications

Volume: 11, P: 1-6
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome

In a clinical trial, Fathi et al. show that a booster vaccination with a vector vaccine candidate against the highly pathogenic Middle East Respiratory Syndrome coronavirus is safe and strongly improves the immunity generated by primary immunization.

Anahita Fathi
Christine Dahlke
Marylyn M. Addo
ResearchOpen Access19 Jul 2022
Nature Communications

Volume: 13, P: 1-12
Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection

Chunyan Wang
Wentao Li
Berend-Jan Bosch
Amendments and CorrectionsOpen Access14 May 2020
Nature Communications

Volume: 11, P: 1
Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)

Duration of infectious SARS-CoV-2 shedding is an important measure for improved disease control. Here, the authors use virus cultures of respiratory tract samples from COVID-19 patients and observe a median shedding duration of 8 days and a drop below 5% after 15,2 days post onset of symptoms.

Jeroen J. A. van Kampen
David A. M. C. van de Vijver
Annemiek A. van der Eijk
ResearchOpen Access11 Jan 2021
Nature Communications

Volume: 12, P: 1-6
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection

There are currently no drugs available to treat SARS-CoV-2 infection. A promising alternative treatment for COVID-19 patients is convalescent plasma. Here, Gharbharan et al. collect covalescent plasma and report no overall clinical benefit for 86 patients hospitalized for COVID-19 and treated with 300 mL convalescent plasma.

Arvind Gharbharan
Carlijn C. E. Jordans
Bart J. A. Rijnders
ResearchOpen Access27 May 2021
Nature Communications

Volume: 12, P: 1-12
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

Here, the authors report the isolation and characterization of two human monoclonal antibodies (mAbs) from immunized mice with trimeric spike ectodomains of three human betacoronaviruses HCoV-OC43, SARS-CoV and MERSCoV, and show that while exhibiting cross-reactivity, the mAbs only neutralize MERS-CoV but not SARS-CoV nor SARS-CoV-2, likely due to the subtle epitope differences in the spike S2 fusion subunit.

Chunyan Wang
Rien van Haperen
Berend-Jan Bosch
ResearchOpen Access17 Mar 2021
Nature Communications

Volume: 12, P: 1-15

Search

Filter By:

Search

Quick links